Baseline characteristics
| . | Favezelimab plus pembrolizumab (MK-4280-003 cohort 2) (N = 27) . | Pembrolizumab monotherapy (KEYNOTE-087) (N = 81) . |
|---|---|---|
| Age, median (range), y | 37 (25-77) | 39 (20-71) |
| Sex, n (%) | ||
| Female | 15 (56) | 34 (42) |
| Male | 12 (44) | 47 (58) |
| Race, n (%) | ||
| Black | 2 (7) | 3 (4) |
| White | 25 (93) | 71 (88) |
| Asian | 0 | 6 (7) |
| Missing | 0 | 1 (1) |
| Region, n (%) | ||
| North America | 13 (48) | 24 (30) |
| Europe | 4 (15) | 49 (60) |
| Rest of world | 10 (37) | 8 (10) |
| ECOG performance status, n (%) | ||
| 0 | 18 (67) | 38 (47) |
| 1 | 9 (33) | 43 (53) |
| Disease subtype, n (%) | ||
| Nodular sclerosing cHL | 20 (74) | 62 (77) |
| Mixed cellularity cHL | 4 (15) | 11 (14) |
| Data missing | 3 (11) | 8 (10) |
| Tumor size at time of randomization (MK-4280-003) or initial progression (KEYNOTE-087), median (range), mm2 | 2819 (234-12 863) | 866 (37-5550) |
| Time from initiation of first-line therapy, median (range), mo | 61.2 (23.8-252.0) | 11.7 (2.3-256.0) |
| Prior lines of therapy, median (range) | 5 (2-5) | 4 (2-11) |
| 2, n (%) | 1 (4) | 12 (15) |
| 3, n (%) | 1 (4) | 26 (32) |
| 4, n (%) | 3 (11) | 20 (25) |
| ≥5, n (%) | 22 (81) | 23 (28) |
| Time to initial disease progression, median (range), wk | 20.4 (7.4-60.3)∗ | 12.0 (4.7-64.9) |
| Time from last dose of anti–PD-1 therapy to randomization (MK-4280-003) or initial progression event (KEYNOTE-087), median (range), wk | 17.6 (3.0-226.1) | 2.1 (0-5.6) |
| Received chemotherapy† /ADC‡ between randomization and prior anti–PD-1 therapy, n (%) | 10 (37) | NA |
| Time from last dose of chemotherapy/ADC, median (range), wk | 18.1 (2.9-101.9) | NA |
| Time from last dose of anti–PD-1 therapy, median (range), wk | 62.1 (16.0-131.1) | NA |
| Prior stem cell transplantation, n (%) | 21 (78) | 50 (62) |
| . | Favezelimab plus pembrolizumab (MK-4280-003 cohort 2) (N = 27) . | Pembrolizumab monotherapy (KEYNOTE-087) (N = 81) . |
|---|---|---|
| Age, median (range), y | 37 (25-77) | 39 (20-71) |
| Sex, n (%) | ||
| Female | 15 (56) | 34 (42) |
| Male | 12 (44) | 47 (58) |
| Race, n (%) | ||
| Black | 2 (7) | 3 (4) |
| White | 25 (93) | 71 (88) |
| Asian | 0 | 6 (7) |
| Missing | 0 | 1 (1) |
| Region, n (%) | ||
| North America | 13 (48) | 24 (30) |
| Europe | 4 (15) | 49 (60) |
| Rest of world | 10 (37) | 8 (10) |
| ECOG performance status, n (%) | ||
| 0 | 18 (67) | 38 (47) |
| 1 | 9 (33) | 43 (53) |
| Disease subtype, n (%) | ||
| Nodular sclerosing cHL | 20 (74) | 62 (77) |
| Mixed cellularity cHL | 4 (15) | 11 (14) |
| Data missing | 3 (11) | 8 (10) |
| Tumor size at time of randomization (MK-4280-003) or initial progression (KEYNOTE-087), median (range), mm2 | 2819 (234-12 863) | 866 (37-5550) |
| Time from initiation of first-line therapy, median (range), mo | 61.2 (23.8-252.0) | 11.7 (2.3-256.0) |
| Prior lines of therapy, median (range) | 5 (2-5) | 4 (2-11) |
| 2, n (%) | 1 (4) | 12 (15) |
| 3, n (%) | 1 (4) | 26 (32) |
| 4, n (%) | 3 (11) | 20 (25) |
| ≥5, n (%) | 22 (81) | 23 (28) |
| Time to initial disease progression, median (range), wk | 20.4 (7.4-60.3)∗ | 12.0 (4.7-64.9) |
| Time from last dose of anti–PD-1 therapy to randomization (MK-4280-003) or initial progression event (KEYNOTE-087), median (range), wk | 17.6 (3.0-226.1) | 2.1 (0-5.6) |
| Received chemotherapy† /ADC‡ between randomization and prior anti–PD-1 therapy, n (%) | 10 (37) | NA |
| Time from last dose of chemotherapy/ADC, median (range), wk | 18.1 (2.9-101.9) | NA |
| Time from last dose of anti–PD-1 therapy, median (range), wk | 62.1 (16.0-131.1) | NA |
| Prior stem cell transplantation, n (%) | 21 (78) | 50 (62) |
ADC, antibody-drug conjugates; cHL, classical Hodgkin lymphoma; NA, not applicable.
For participants in MK-4280-003, the median time from enrollment to initial disease progression was 59.4 weeks (range, 36.1-60.3) for participants whose last anti–PD-1 dose was ≤12 weeks prior to randomization (n = 3), and 12.3 weeks (range, 7.4-46.6) for participants whose last anti–PD-1 dose was >12 weeks prior to randomization (n = 10). Fourteen participants did not have disease progression until the time of censoring.
Included gemcitabine, dacarbazine, doxorubicin, and cyclophosphamide.
Included brentuximab vedotin and camidanlumab tesirine.